Infections are a leading cause of mortality in patients who are immunosuppressed following a transplant. Antifungal prophylaxis may be indicated but be aware that this can affect the performance of some biomarker tests and may carry a high risk of serious drug interactions.
![](http://es.en.fungaleducation.org/wp-content/uploads/sites/3/2020/07/spacer-tricolor2.png)
Solid organ transplants
Surveillance of 1063 patients from 15 TRANSNET centres across the US (Pappas et al, 2010) showed that overall incidence of invasive fungal infections was around 3% in the first year.
![](http://es.en.fungaleducation.org/wp-content/uploads/sites/3/2019/12/Pappas2010IFItransplant.png)
![](http://es.en.fungaleducation.org/wp-content/uploads/sites/3/2020/07/spacer-tricolor2.png)
Haemato-Oncology
Rates of IFI vary between different types of haematological malignancy (Pagano et al, 2006).
AML | ALL | CML | CLL | Lymphoma | Multiple myeloma |
12% | 6.5% | 2.5% | 0.5% | 0.7-1.5% | 0.5% |
You may also be interested in these topics
Invasive aspergillosis
Candidaemia
P. jirovecii pneumonia
Mucormycosis
Oesophageal candidiasis
Guidelines on prophylaxis and empirical therapy